Kratom and cannabidiol (CBD) are two naturally derived substances often discussed for their potential roles in pain management and mental well-being. Although both are plant-based and used by people seeking alternative therapies, the two differ fundamentally in their biological effects, chemical makeup, regulatory status, and safety profiles. This article unpacks those distinctions using verified scientific and governmental sources to clarify what is currently known—and not yet known—about kratom and CBD.
What Kratom Is
Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia, part of the coffee family. Its leaves contain compounds that can influence mood and body functions when ingested. According to the National Institute on Drug Abuse (NIDA), kratom’s primary active alkaloids—mitragynine and 7-hydroxymitragynine—act on opioid receptors in the brain, potentially producing stimulation at low doses and sedation at high doses.
Despite its growing popularity among self-treating users for relief from pain, anxiety, or opioid withdrawal symptoms, kratom is not approved by the U.S. Food and Drug Administration (FDA)for any medical use. The Drug Enforcement Administration (DEA) classifies it as a “Drug and Chemical of Concern,” citing safety issues and potential for abuse. Legal status varies by state, and users are advised to verify local laws before purchasing or consuming it.
What CBD Is
Cannabidiol (CBD) is a prominent non-psychoactive compound found in the Cannabis sativaplant. Unlike tetrahydrocannabinol (THC), it does not induce a high. The National Institutes of Health (NIH) notes that CBD interacts with the body’s endocannabinoid system—a network influencing pain, mood, appetite, and immune response.
Most commercially available CBD products in the United States are derived from hemp, a variety of cannabis that contains less than 0.3% THC, as defined by the 2018 Farm Bill. The FDA has approved only one CBD-based prescription drug—Epidiolex—which treats rare forms of epilepsy. While a wide range of CBD products are sold as supplements and topicals, they are not FDA-regulated for safety or efficacy.
How Each Works in the Body
Kratom and CBD interact with the human body through distinct mechanisms. The alkaloids in kratom bind primarily to mu-opioid receptors—similar to drugs like morphine or codeine—but with unique pharmacological differences that are still being studied (NIDA). These interactions can produce energy, alertness, and elevated mood in small doses, or sedation and pain relief in higher amounts.
CBD, in contrast, affects multiple neurotransmitter systems without engaging opioid receptors. Research published in the National Library of Medicine suggests CBD modulates serotonin signaling and influences brain regions linked to anxiety and mood regulation. Scientists continue to explore its effects on inflammation, neural protection, and even immune balance.
Therapeutic Promise and Current Limitations
Advocates of kratom often cite anecdotal experiences of pain control and relief from opioid withdrawal symptoms. Yet formal human studies are limited. The FDA cautions that kratom may carry risks of addiction and toxicity without proven therapeutic benefits.
CBD, meanwhile, has broader clinical documentation. Peer-reviewed studies support its efficacy in seizure reduction and suggest possible benefits in chronic pain and anxiety management (ScienceDirect). However, its over-the-counter forms are not standardized, and concentrations differ widely across products, often leading to inconsistent results.
Differences in Side Effects and Health Risks
Kratom’s potential side effects are well-documented in toxicology reports. According to the FDAand DEA, adverse effects can include nausea, vomiting, dry mouth, sweating, constipation, rapid heartbeat, and drowsiness. Long-term use may increase risk of liver damage, seizures, and in rare cases psychosis or heart issues (Frontiers in Pharmacology, 2021). Instances of dependence and withdrawal have been observed in chronic users.
CBD is generally better tolerated, although not without risks. The FDA cites possible side effects such as liver injury, fatigue, or medication interactions that alter drug metabolism. Animal studies have indicated potential impacts on male reproductive health, but human data remain limited.
Legal Landscape in the United States
The legality of both substances hinges on jurisdiction and context. CBD derived from hemp is federally legal if it contains less than 0.3% THC, but state laws still differ on labeling and distribution. Kratom’s legality is less uniform—banned in several states and municipalities, while permitted in others. The American Kratom Association (AKA) has lobbied for state-level regulation under its Kratom Consumer Protection Act, aiming to standardize purity testing and labeling.
Federal agencies, however, remain cautious. The FDA continues to issue consumer advisories against kratom use, citing contamination reports and unregulated marketing. While CBD’s regulatory path has advanced further, with Epidiolex marking a pharmaceutical milestone, the agency emphasizes that most CBD products on the market lack verified safety data.
Comparison of Key Characteristics
| Aspect | Kratom | CBD |
|---|---|---|
| Plant Source | Mitragyna speciosa (coffee family) | Cannabis sativa (hemp variety) |
| Primary Compounds | Mitragynine, 7-hydroxymitragynine | Cannabidiol (CBD) |
| Mechanism of Action | Binds to opioid receptors | Modulates endocannabinoid and serotonin systems |
| Intended Uses (self-reported) | Pain, mood elevation, anxiety, opioid withdrawal | Pain, seizures, anxiety, inflammation |
| Legal Status (U.S.) | Unregulated federally; banned in some states | Federally legal if hemp-derived (<0.3% THC) |
| FDA Approval | None | Epidiolex approved for epilepsy |
| Potential Risks | Dependence, liver toxicity, heart issues | Liver injury, drug interactions |
| Research Stage | Limited human studies | Extensive preclinical and clinical data |
Scientific Uncertainty and Cautionary Guidance
Despite growing consumer enthusiasm, experts warn that both substances require further research. Neither kratom nor CBD should be used as a substitute for professional medical treatment without supervision. People using prescription medications should consult healthcare providers to avoid harmful interactions.
The Centers for Disease Control and Prevention (CDC) notes that while kratom’s involvement in overdose deaths is rare, it can compound risks when mixed with other depressants or opioids. Similarly, CBD can alter how the liver metabolizes medications, including blood thinners and antiepileptic drugs.
Evolving Regulation and Research Outlook
Scientific interest in kratom is accelerating. Ongoing NIH-funded studies aim to clarify its potential role in pain management and addiction recovery while assessing its abuse liability. In parallel, CBD research continues to expand into fields like neurodegenerative disease and inflammation control.
For now, the main takeaway remains caution. The FDA warns consumers that unregulated kratom and CBD products may contain contaminants or misrepresented concentrations. Verified third-party testing and legal compliance should be standard for any consumer considering use.
The Bottom Line
While both kratom and CBD originate from plants and attract interest for their perceived natural health benefits, the similarities end there. CBD enjoys limited but recognized medical acceptance through pharmaceutical approval, while kratom remains under intense scrutiny due to safety concerns and lack of regulation.
Both substances are under active scientific investigation, but consumers should remain aware that legality does not equate to safety. As researchers and regulatory agencies continue to gather evidence, those seeking to use either should rely on reputable sources, consult healthcare professionals, and ensure the products they select meet current regulatory standards for purity and labeling.
For further reading, see authoritative resources such as the FDA’s guidance on CBD and kratom, NIDA’s kratom research overview, and the DEA’s drug profile on kratom.